Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut d… Read more
Pieris Pharmaceuticals Inc (PIRS) - Total Liabilities
Latest total liabilities as of September 2024: $4.25 Million USD
Based on the latest financial reports, Pieris Pharmaceuticals Inc (PIRS) has total liabilities worth $4.25 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pieris Pharmaceuticals Inc - Total Liabilities Trend (2012–2023)
This chart illustrates how Pieris Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pieris Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Pieris Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Betamek Bhd
KLSE:0263
|
Malaysia | RM61.35 Million |
|
Jaya Agra Wattie Tbk
JK:JAWA
|
Indonesia | Rp2.56 Trillion |
|
Pelangio Exploration Inc
PINK:PGXPF
|
USA | $543.51K |
|
Silvair Inc
WAR:SVRS
|
Poland | zł6.29 Million |
|
UniPharma Co., Ltd.
TWO:6621
|
Taiwan | NT$40.37 Million |
|
FuelPositive Corp
OTCQB:NHHHF
|
USA | $2.86 Million |
|
AMJ Global Technology
PINK:AMJT
|
USA | $1.19 Million |
|
Arcure SA
PA:ALCUR
|
France | €12.70 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Pieris Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pieris Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pieris Pharmaceuticals Inc (2012–2023)
The table below shows the annual total liabilities of Pieris Pharmaceuticals Inc from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $11.92 Million | -82.35% |
| 2022-12-31 | $67.56 Million | -34.28% |
| 2021-12-31 | $102.81 Million | +38.96% |
| 2020-12-31 | $73.98 Million | -17.56% |
| 2019-12-31 | $89.75 Million | -11.50% |
| 2018-12-31 | $101.41 Million | +9.80% |
| 2017-12-31 | $92.35 Million | +838.91% |
| 2016-12-31 | $9.84 Million | +248.59% |
| 2015-12-31 | $2.82 Million | -27.23% |
| 2014-12-31 | $3.88 Million | -42.05% |
| 2013-12-31 | $6.69 Million | -27.68% |
| 2012-12-31 | $9.25 Million | -- |